# N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

> **NCT00780962** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 399 (actual)

## Conditions studied

- Radiocontrast Nephropathy

## Interventions

- **DRUG:** N-Acetylcysteine (NAC)
- **DRUG:** 0.9% Sodium-chloride

## Key facts

- **NCT ID:** NCT00780962
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-16
- **Primary completion:** 2010-08-09
- **Final completion:** 2010-08-09
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2024-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780962, "N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00780962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*